{"entity":{"id":"oncoveryx","kind":"drug","name":"OncoVeryx (PredOmix)","aka":["OncoVeryx-F","PredOmix metabolome test"],"tldr":"An Indian blood test that reads thousands of small molecules in serum; its developer reports about 98% accuracy for 30 cancers, figures that have not been checked independently.","summary":"PredOmix Technologies of Gurugram, India, with a Singapore affiliate, has published a version for four cancers in women (Gupta et al., Scientific Reports 2022), a version for 15 cancers in women reported as identifying all cancer-positive samples with more than 99% accuracy (Gupta et al., Scientific Reports 2023), and, in an investigator-initiated trial with HCG cancer centres of 6,445 people (CTRI/2023/03/050316; Nagarkar et al., Cancer Reports 2024), a version for 30 cancers in women and men with an average accuracy of about 98% that did not vary by stage. A study of OncoVeryx-F for ovarian cancer (Nagarkar et al., International Journal of Women's Health 2024) reported stage I detection accuracy above 98%. None of the abstracts gives sensitivity at a stated specificity, cancers counted by type and stage, or a screening-population result. Company employees wrote the papers. No CDSCO or other regulatory status, availability or price was found.","status":"emerging","asOf":"2026-11-03","links":[{"label":"Nagarkar et al., Cancer Reports 2024 (30 cancers)","url":"https://doi.org/10.1002/cnr2.70042"},{"label":"Gupta et al., Scientific Reports 2023 (15 cancers in women)","url":"https://doi.org/10.1038/s41598-023-46553-7"},{"label":"Gupta et al., Scientific Reports 2022 (four cancers in women)","url":"https://doi.org/10.1038/s41598-022-06274-9"},{"label":"Nagarkar et al., International Journal of Women's Health 2024 (OncoVeryx-F, ovarian)","url":"https://doi.org/10.2147/IJWH.S444258"}],"tags":["test","mced","evidence:insufficient"],"related":[],"cancers":[],"sections":[],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":[],"companies":["predomix"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-predomix-metabolome-cancer-rep-2024"],"journals":[],"dependsOn":[],"notes":["Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.","Accuracy near 98 to 99% at every stage would be far above any other multi-cancer test; the figures are developer-reported and not independently replicated.","What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening)."],"brand":"OncoVeryx","modality":"Multi-cancer early detection blood test (serum metabolomics with machine learning)","mechanism":"Untargeted mass spectrometry of serum metabolites, classified by machine learning first as cancer or no cancer and then by tissue of origin.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/oncoveryx/","neighbours":{"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"company":[{"id":"predomix","kind":"company","name":"PredOmix","route":"/companies/predomix/"}],"paper":[{"id":"paper-predomix-metabolome-cancer-rep-2024","kind":"paper","name":"Development of a Serum Metabolome-Based Test for Early-Stage Detection of Multiple Cancers","route":"/key-papers/paper-predomix-metabolome-cancer-rep-2024/"}]}}